Why Oragenics Inc’s (OGEN) Stock Is Up 5363.77%
As of Monday, January 23, Oragenics Inc’s OGEN share price has surged by 5363.77%, which has investors questioning if this is right time to sell.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Commentary & Analysis
Is Oragenics Inc Stock (OGEN) a Good Investment?
Learn more about Oragenics Inc’s (OGEN) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Dylan Dease
Financial Summary
| Share Statistics | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.6 | $214.3 | 2% |
|
| Shares Out (Mil) | 4.4 | 53.9 | 13% |
|
| Institutional Ownership | 93.3% | 92.9% | 63% |
|
| Float (Mil) | 4.4 | 41.4 | 11% |
|
| Beta | 1.24 | 0.96 | 73% |
|
| Avg Daily Volume (000s) | 23 | 506 | 22% |
|
| Price Change (52-week) |
(69.1%) | 43.9% | 13% |
|
| Growth | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 18.0% | (10.1%) | 70% |
|
| EPS (5yr) | 64.8% | 15.8% | 97 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.8% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($44) | 29% |
|
| EPS (TTM) | ($2.512) | ($1.500) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($34) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $172 | 3% |
|
| Valuation | OGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.43 | 2.00 | 9% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | OGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (264.2%) | (47.5%) | 1% |
|
| ROE | na | (53.3%) | na |
|
| Liabilities to Assets | 33.2% | 29.6% | 24% |
|
| F-Score | 2 | 2 | 7% |
|
Passing Stock Screens
As of 11/5/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 2.6% |
| +/- S&P 500: | -4.8 |
